Momenta Pharmaceuticals (MNTA) Earning Somewhat Positive Press Coverage, Report Shows

Press coverage about Momenta Pharmaceuticals (NASDAQ:MNTA) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.5676095540787 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $15.75 on Tuesday. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.90. The company has a market capitalization of $1,200.00, a price-to-earnings ratio of -19.69 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. During the same period in the prior year, the business posted ($0.26) earnings per share. Momenta Pharmaceuticals’s revenue was down 17.3% compared to the same quarter last year. sell-side analysts predict that Momenta Pharmaceuticals will post -1.16 EPS for the current fiscal year.

Several brokerages have recently weighed in on MNTA. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 9th. JPMorgan Chase & Co. restated a “hold” rating and issued a $14.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. ValuEngine lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Goldman Sachs Group began coverage on Momenta Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 price objective for the company. Finally, Robert W. Baird lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the company from $22.00 to $15.00 in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. Momenta Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $15.00.

In other news, Director Elizabeth Stoner sold 5,500 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the sale, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 4,116 shares of the stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total value of $54,948.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,505 shares of company stock valued at $685,923. 4.40% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals (MNTA) Earning Somewhat Positive Press Coverage, Report Shows” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/16/momenta-pharmaceuticals-mnta-earning-somewhat-positive-press-coverage-report-shows.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit